Technical Trend Overview and Price Movement
As of 2 January 2026, Dr Reddys Laboratories Ltd closed at ₹1,252.40, down 1.47% from the previous close of ₹1,271.05. The stock’s intraday range was relatively narrow, with a low of ₹1,249.00 and a high of ₹1,266.40. This decline contrasts with the Sensex’s marginal fall of 0.04% over the year-to-date period, signalling a relative underperformance in the short term. Over the past week and month, the stock has also lagged the benchmark, with returns of -1.10% and -0.60% respectively, compared to Sensex returns of -0.26% and -0.53% for the same periods.
Longer-term returns reveal a more nuanced picture. Over one year, Dr Reddys has declined by 8.55%, while the Sensex gained 8.51%. However, over three years, the stock has outperformed the benchmark with a 47.88% return versus 40.02% for the Sensex. The five-year and ten-year returns show the stock lagging the broader market, with 19.49% versus 77.96% and 101.62% versus 225.63% respectively. These figures highlight the stock’s mixed performance trajectory, with recent weakness contrasting with solid medium-term gains.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator presents a split view. On a weekly basis, the MACD remains bullish, suggesting some underlying positive momentum in the medium term. However, the monthly MACD has turned mildly bearish, indicating a weakening trend over a longer horizon. This divergence suggests that while short-term momentum may still support the stock, the broader trend is losing strength.
The Know Sure Thing (KST) indicator aligns with this assessment, showing bearish signals on the weekly chart and mildly bearish readings monthly. This further confirms the waning momentum and potential for continued downward pressure if the trend persists.
RSI and Overbought/Oversold Conditions
The Relative Strength Index (RSI) currently offers no clear signal on either weekly or monthly timeframes, indicating that the stock is neither overbought nor oversold. This neutral RSI suggests that price movements are not yet extreme, leaving room for either a rebound or further decline depending on other technical and fundamental factors.
Bollinger Bands and Volatility
Bollinger Bands on both weekly and monthly charts are bearish, signalling increased volatility and a tendency for prices to trade near the lower band. This pattern often precedes further downside or consolidation, reflecting investor caution and potential selling pressure in the pharmaceutical sector.
Moving Averages and Daily Trend
On a daily basis, moving averages provide a mildly bullish signal. This suggests that despite the broader bearish tendencies, short-term price action is showing some resilience. The stock’s current price of ₹1,252.40 remains below its 52-week high of ₹1,404.60 but comfortably above the 52-week low of ₹1,025.90, indicating a moderate recovery potential if momentum shifts favourably.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Volume and Dow Theory Signals
On-Balance Volume (OBV) readings are mildly bearish on a weekly basis, indicating that volume trends are not supporting a strong upward price movement. Monthly OBV shows no clear trend, reflecting indecision among investors. Dow Theory assessments mirror this uncertainty, with weekly signals mildly bearish and monthly readings showing no definitive trend. This combination suggests that the stock is currently in a phase of consolidation or mild decline rather than a clear directional move.
Mojo Score and Grade Revision
MarketsMOJO’s proprietary scoring system has upgraded Dr Reddys Laboratories Ltd from a Sell to a Hold rating as of 1 December 2025, with a current Mojo Score of 51.0. This reflects a cautious stance, recognising the stock’s mixed technical signals and moderate market capitalisation grade of 1. The upgrade from Sell to Hold indicates some improvement in outlook, but the overall assessment remains neutral, advising investors to monitor developments closely before committing fresh capital.
Sector and Industry Context
Operating within the Pharmaceuticals & Biotechnology sector, Dr Reddys Laboratories faces sector-specific challenges including regulatory scrutiny, pricing pressures, and competitive innovation. The sector’s performance often correlates with broader healthcare trends and global economic conditions. Given the current mildly bearish technical signals and the stock’s recent underperformance relative to the Sensex, investors should weigh sector dynamics carefully alongside company-specific factors.
Considering Dr Reddys Laboratories Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this large-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Investor Takeaway and Outlook
Dr Reddys Laboratories Ltd currently exhibits a complex technical profile with a shift towards mild bearishness in key momentum indicators, despite some short-term bullish signals on daily moving averages and weekly MACD. The absence of RSI extremes suggests the stock is not yet oversold, leaving room for either a corrective bounce or further downside depending on market catalysts.
Investors should consider the stock’s relative underperformance against the Sensex in the near term, balanced against its solid medium-term returns. The upgrade to a Hold rating by MarketsMOJO reflects this cautious optimism, recommending a watchful approach rather than aggressive accumulation.
Given the pharmaceutical sector’s inherent volatility and regulatory risks, close monitoring of technical indicators alongside fundamental developments will be essential. Should the monthly MACD and Bollinger Bands continue to deteriorate, the stock may face further pressure. Conversely, a sustained recovery in daily moving averages and volume could signal a return to more constructive momentum.
Overall, Dr Reddys Laboratories remains a stock with mixed signals, where technical momentum is shifting but not decisively so. Investors are advised to maintain a balanced view, considering both the potential for recovery and the risks of continued consolidation or decline.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
